The effect of Loratadine and Naproxen on prevention of pain caused by Granulocyte colony stimulating factor in cancer patients

Comparison of the effect of Non-steroidal analgesics alone with Loratadine combined with Non-steroidal analgesics in the prevention of pain caused by Granulocyte colony stimulating factor in cancer patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190922044848N1

Enrollment

Registered

2019-10-05

Start date

2018-11-11

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Breast cancer. Condition 2: Multiple myeloma. Condition 3: Hodgkin lymphoma. Condition 4: Follicular lymphoma. Condition 5: Non-follicular lymphoma. Condition 6: Ovarian cancer. Condition 7: Vaginal cancer. Condition 8: Bladder cancer. Malignant neoplasm of breast Multiple myeloma and malignant plasma cell neoplasms Hodgkin lymphoma Follicular lymphoma Non-follicular lymphoma Malignant neoplasm of ovary Malignant neoplasm of vagina Malignant neoplasm of bladder

Interventions

Intervention 1: Intervention group: 35 cancer patients are randomly assigned into this group. Naproxen 500 milligram twice daily with Loratadine 10 milligram once daily is prescribed orally for 8 days

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who are 18 years of age or older Patients with malignancy confirmed by pathological reports Patients receiving chemotherapy drugs and Granulocyte colony stimulating factor

Exclusion criteria

Exclusion criteria: Patients with a history of chronic pain Patients with a history of gastrointestinal bleeding or ulcers Patients who have a history of intolerance or hypersensitivity to antihistamines

Design outcomes

Primary

Measure	Time frame
Pain severity due to Granulocyte colony stimulating factor. Timepoint: Measurement of pain severity 9 days after receiving Granulocyte colony stimulating factor. Method of measurement: McGill pain questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Atefrad

Karaj University of Medical Sciences

fa.atefrad@gmail.com+98 21 8840 7199

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026